Headlines

Motley Rice filed a motion opposing the dismissal of defendants Kingdom of Saudi Arabia and the Saudi High Commission from In re Terrorist Attacks.

Motley Rice is pleased to announce that the plaintiffs in the class action lawsuit <em>Kellerman v. Marion Bass Securities Corp. </em>have reached settlement agreements.

The New York Times reports that medical device manufacturer Johnson & Johnson continued to market artificial hip implants abroad after the FDA prohibited the sale of these devices in the United States.

On Friday, Jan. 20, 2012, a U.S. congressional committee was again asked to further "examine medical devices that have developed serious defects after being implanted in patients."

In a recent article that ran in Lawyers Weekly USA, Motley Rice medical attorney Fidelma Fitzpatrick was interviewed about the first case to go to trial involving a pelvic mesh/transvaginal mesh product.

On Feb. 25, 2013, after five days of deliberation, a New Jersey jury awarded $3.5 million in compensatory damages to the plaintiffs in a transvaginal/pelvic mesh lawsuit against pharmaceutical giant Johnson & Johnson.

A recent, alarming article by Bloomberg suggests that C.R. Bard’s (BCR) Davol unit knew that the plastic it used in its Avaulta line of transvaginal (pelvic) mesh devices was unsafe to be permanently implanted in humans.

Motley Rice has reached an Agreement in Principle to settle with transvaginal mesh (TVM) device manufacturer American Medical Systems, Inc. (AMS) and parent company Endo International plc.

It is estimated that more than two million women in the United States have used the Mirena IUD device in the past ten years.

On Monday, April 7, a federal court jury in Louisiana decided that Takeda Pharmaceuticals and Eli Lilly hid the risks of bladder cancer from the diabetes drug, Actos.